Across TCGA pan-cancer cohorts, PRR5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRR5 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher PRR5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRR5 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

PRAD, STAD, and COAD are the cancer types where PRR5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.200	0.775	.013	6	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
COAD	OS	Median	II,III,IV	0.172	0.859	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PRR5 tumor-vs-normal RNA expression · all PRR5 data types